| Title |
Lymphomatoid Granulomatosis and Other Epstein-Barr Virus Associated Lymphoproliferative Processes
|
|---|---|
| Published in |
Current Hematologic Malignancy Reports, July 2012
|
| DOI | 10.1007/s11899-012-0132-3 |
| Pubmed ID | |
| Authors |
Kieron Dunleavy, Mark Roschewski, Wyndham H. Wilson |
| Abstract |
We now recognize that the Epstein-Barr virus (EBV), which is a member of the γ- herpesvirus family, plays a pivotal role in the development of several lymphomas and lymphoproliferative disorders that include B-cell, T-cell and NK-cell processes. While over recent years, EBV associated lymphomas that arise in patients with known defects in cellular immunity are relatively well characterized, these diseases are becoming increasingly recognized in patients without overt immunodeficiency. Improved understanding of the biology of these lymphomas including elucidating the role that EBV plays in their pathogenesis has paved the way for improved therapies targeted at critical signaling pathways as well as the development of novel cellular therapies. In this review, we focus on recent progress that has been made in the biology and treatment of the rare EBV-associated disorder lymphomatoid granulomatosis (LYG) and also discuss other EBV-associated processes that occur in both immunocompetent and immunocompromised hosts. |
Mendeley readers
The data shown below were compiled from readership statistics for 38 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 3% |
| Unknown | 37 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 7 | 18% |
| Student > Doctoral Student | 6 | 16% |
| Student > Postgraduate | 5 | 13% |
| Student > Bachelor | 4 | 11% |
| Student > Ph. D. Student | 4 | 11% |
| Other | 8 | 21% |
| Unknown | 4 | 11% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 23 | 61% |
| Agricultural and Biological Sciences | 4 | 11% |
| Biochemistry, Genetics and Molecular Biology | 2 | 5% |
| Neuroscience | 2 | 5% |
| Engineering | 1 | 3% |
| Other | 0 | 0% |
| Unknown | 6 | 16% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 September 2021.
All research outputs
#7,453,479
of 22,787,797 outputs
Outputs from Current Hematologic Malignancy Reports
#165
of 427 outputs
Outputs of similar age
#54,649
of 163,989 outputs
Outputs of similar age from Current Hematologic Malignancy Reports
#2
of 5 outputs
Altmetric has tracked 22,787,797 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 427 research outputs from this source. They receive a mean Attention Score of 4.9. This one has gotten more attention than average, scoring higher than 51% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 163,989 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 47th percentile – i.e., 47% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one. This one has scored higher than 3 of them.